


# Supplementary Material to Rühl et al. "Thrombin inhibition profiles in healthy individuals and thrombophilic patients" (Thromb Haemost 2012; 107.4)



Suppl. Figure 1: Influence of antithrombin levels on thrombin generation parameters. Plasma samples containing the indicated concentrations of antithrombin were analyzed by the CAT assay. **A.** lag time (●). **B.** time to peak (▼) **C.** start-to-tail time (○). **D.** endogenous thrombin potential (ETP) (△). **E.** maximum thrombin peak (▽).

**Suppl. Table 1: Characteristics of the thrombophilic patients.**

No.	Age (years)	Sex	Thromboembolic events	Thrombophilic risk factors
1	42	M	DVT	Het. FVL mutation, HR2-haplotype
2	37	M	DVT + PE	Antithrombin deficiency
3	57	F	DVT, recurrent PE	-
4	34	F	DVT	-
5	57	M	DVT	-
6	38	F	DVT + PE	APA
7	25	F	CVST	-
8	32	F	PE	-
9	29	M	DVT + PE, recurrent DVT	-
10	49	M	DVT	-
11	40	M	DVT + PE	-
12	37	F	DVT	-
13	31	F	DVT	-
14	41	F	DVT	-
15	65	F	Recurrent DVT	-
16	19	F	DVT	Het. FVL mutation
17	23	F	DVT, PE	Het. FVL mutation
18	55	M	Recurrent DVT	-
19	22	F	DVT + PE	-
20	35	M	DVT + PE	-
21	52	M	DVT, PE	-
22	50	M	DVT + PE, recurrent PE	-
23	47	M	DVT + PE	-
24	73	F	DVT, recurrent DVT + PE	-
25	40	M	PE	APA
26	43	F	DVT + PE	Het. FVL mutation, APA
27	45	F	Retinal vein thrombosis	APA
28	47	F	TIA	APA
29	66	F	Recurrent PE	APA
30	38	M	DVT + PE	Het. FVL mutation, APA
31	58	M	DVT	APA
32	26	F	DVT	APA
33	57	F	TIA	APA
34	34	F	Recurrent DVT	APA
35	32	F	Recurrent DVT	APA
36	45	F	DVT	APA
37	33	F	DVT, recurrent PE, renal infarction	APA
38	66	F	Retinal vein thrombosis	APA
39	41	F	PE	APA

APA, antiphospholipid antibodies; DVT, deep-vein thrombosis; FVL, factor V Leiden; PE, pulmonary embolism; TIA, transitory ischaemic attack.

**Suppl. Table 2: Results of antiphospholipid antibody testing.**

No.	functional tests for lupus anticoagulant positive	aPL titre		aPT titre		a $\beta$ 2 titre	
		IgG <sup>1</sup> < 6.3	IgM <sup>2</sup> < 5.2	IgG <sup>1</sup> < 4.5	IgM <sup>2</sup> < 7.0	IgG <sup>1</sup> < 20	IgM <sup>2</sup> < 20
6	aPTT, dRVVT	48.0	5.8	25.6	6.1	n. a.	n. a.
25	dRVVT	18.1	0	46.2	35.0	n. a.	n. a.
26	-	0	0	8.0	39.1	n. a.	n. a.
27	dRVVT	72.8	82.3	41.4	77.5	n. a.	n. a.
28	-	5.7	18.9	8.5	48.7	n. a.	n. a.
29	dRVTT	4.1	41.3	13.1	157.7	n. a.	n. a.
30	dRVVT	7.6	24.6	11.4	80.5	n. a.	n. a.
31	aPTT, KCT, dRVVT	41.3	122.4	37.0	221.2	n. a.	n. a.
32	aPTT, KCT, dRVVT	40.0	6.7	25.7	5.3	145.7	11.3
33	aPTT, dRVVT	1.7	5.6	23.5	8.4	n. a.	n. a.
34	aPTT, dRVVT	45.1	2.8	35.2	2.8	147.1	1.8
35	aPTT, dRVVT	7.5	20.8	6.8	33.5	n. a.	n. a.
36	aPTT, KCT, dRVVT	111.1	66.6	148.4	225.8	n. a.	n. a.
37	aPTT, KCT, dRVVT	34.1	16.2	5.7	20.4	n. a.	n. a.
38	-	4.1	6.4	10.5	39.3	n. a.	n. a.
39	-	5.3	16.3	5.8	34.1	n. a.	n. a.

<sup>1</sup> GPL-U/ml; <sup>2</sup> MPL-U/ml; aPTT, (Lupus-sensitive) activated partial thromboplastin time; dRVVT, diluted Russell's viper venom test; KCT, kaolin clotting time; aPL, antiphospholipid-screen; aPT, anti-prothrombin-phospholipid; a $\beta$ 2,  $\beta$ 2-glycoprotein antibody; n. a., not available.